uniQure Prices Upsized $225M Public Offering at Discount to Market

summarizeSummary

uniQure priced an upsized $225 million public offering of ordinary shares at $45.50 per share, a discount to its recent market price, to fund commercialization and development activities.

check_boxKey Events · Financing and Capital Events · QURE

• Offering Priced and Upsized

  uniQure priced an upsized public offering of 4,945,055 ordinary shares at $45.50 per share, raising approximately $225 million in gross proceeds. This finalizes the terms of the offering initially announced on June 22, 2026.

• Discounted Pricing

  The offering price of $45.50 per share represents a discount compared to the last reported sale price of $49.04 on June 23, 2026.

• Significant Dilution

  The offering represents a substantial capital raise relative to the company's market capitalization, with potential for further dilution if underwriters exercise their option to purchase an additional 741,758 shares.

• Strategic Use of Proceeds

  Net proceeds of approximately $211.5 million are intended to fund commercialization readiness for AMT-130, its confirmatory study, development of other clinical candidates, and general corporate purposes.

auto_awesomeAnalysis · QURE · Life Sciences

uniQure has finalized the terms of its public offering, upsizing it to $225 million. The offering is priced at a discount to the last reported sale price, indicating a significant capital raise that will be dilutive to existing shareholders. The proceeds are earmarked for critical activities including commercialization readiness for AMT-130, funding its confirmatory study, and advancing other clinical candidates, which are essential following recent positive regulatory developments for AMT-130.